127 related articles for article (PubMed ID: 36193649)
1. Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Luo MY; Zhou Y; Gu WM; Wang C; Shen NX; Dong JK; Lei HM; Tang YB; Liang Q; Zou JH; Xu L; Ma P; Zhuang G; Bi L; Xu L; Zhu L; Chen HZ; Shen Y
Cancer Res; 2022 Oct; 82(19):3516-3531. PubMed ID: 36193649
[TBL] [Abstract][Full Text] [Related]
2. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas.
Lei HM; Zhang KR; Wang CH; Wang Y; Zhuang GL; Lu LM; Zhang J; Shen Y; Chen HZ; Zhu L
Theranostics; 2019; 9(24):7122-7139. PubMed ID: 31695757
[No Abstract] [Full Text] [Related]
4. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Liang Q; Gong M; Zou JH; Luo MY; Jiang LL; Wang C; Shen NX; Zhang MC; Xu L; Lei HM; Zhang KR; Zhang R; Zhuang G; Zhu L; Chen HZ; Zhou L; Shen Y
Drug Resist Updat; 2023 May; 68():100957. PubMed ID: 36990047
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
6. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Cheng C; Zhao Y; Schaafsma E; Weng YL; Amos C
Int J Cancer; 2020 Nov; 147(9):2621-2633. PubMed ID: 32406930
[TBL] [Abstract][Full Text] [Related]
7. Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR.
Chang CC; Hsieh TL; Tiong TY; Hsiao CH; Ji AT; Hsu WT; Lee OK; Ho JH
Biomaterials; 2015 Aug; 60():141-50. PubMed ID: 26000960
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis.
Chan YC; Chang YC; Chuang HH; Yang YC; Lin YF; Huang MS; Hsiao M; Yang CJ; Hua KT
Oncogene; 2020 Mar; 39(12):2509-2522. PubMed ID: 31988456
[TBL] [Abstract][Full Text] [Related]
9. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.
Dopeso H; Jiao HK; Cuesta AM; Henze AT; Jurida L; Kracht M; Acker-Palmer A; Garvalov BK; Acker T
Cancer Res; 2018 Apr; 78(7):1805-1819. PubMed ID: 29339541
[TBL] [Abstract][Full Text] [Related]
10. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
11. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
Shan F; Shao Z; Jiang S; Cheng Z
Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
[TBL] [Abstract][Full Text] [Related]
13. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
[TBL] [Abstract][Full Text] [Related]
15. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide DNA Methylation Analysis Reveals
Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
[No Abstract] [Full Text] [Related]
17. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
18. PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells.
Yang Y; Wu J; Cai J; He Z; Yuan J; Zhu X; Li Y; Li M; Guan H
Int J Cancer; 2015 Feb; 136(4):E39-50. PubMed ID: 25142862
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
20. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.
Chiang CT; Demetriou AN; Ung N; Choudhury N; Ghaffarian K; Ruderman DL; Mumenthaler SM
Cancer Lett; 2018 Oct; 434():152-159. PubMed ID: 30036610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
